Free tool
Medicare drug spending
Last checked: Nov 20, 2026Latest source record: 2024 calendar yearSource: CMS (Medicare Part D Spending by Drug : 2024-01-01; Medicare Part B Spending by Drug : 2024-01-01)Methods & limitations
Part D, 2024
$288.7B
Gross drug spending in the dataset
Part B, 2024
$60.8B
Gross drug spending in the dataset
Drugs listed
11
Part D and Part B
Total spending by year
- Part D
- Part B
View as table
| Year | Part D | Part B |
|---|---|---|
| 2020 | $194,092,038,339 | $37,778,829,680 |
| 2021 | $213,513,349,361 | $40,135,340,775 |
| 2022 | $239,779,215,689 | $44,241,259,745 |
| 2023 | $275,808,918,753 | $50,775,853,083 |
| 2024 | $288,667,842,058 | $60,838,164,403 |
Top 11 by total spending
2024 figures. Growth compares with 2023. Per-beneficiary ranks skip drugs with fewer than 11 beneficiaries.
| Drug | Part | Spending | Change | Beneficiaries | Per beneficiary | Per unit |
|---|---|---|---|---|---|---|
| Shingrix Varicella-Zoster Ge/As01b/PF | D | $776M | -36% | 2,933,003 | $264 | $196.56 |
| Savella Milnacipran HCl | D | $59.3M | -3% | 16,606 | $3,572 | $7.96 |
| Oxtellar XR Oxcarbazepine | D | $28.5M | -9% | 2,844 | $10,008 | $17.96 |
| Xcell amnio matrix, per square centimeter · Q4280 | B | $26.8M | n/a | 211 | $126,979 | $1,951.25 |
| M-M-R II Vaccine Measles,Mumps,Rubella Vacc/PF | D | $2.5M | +65% | 20,979 | $117 | $103.86 |
| Varivax Vaccine Varicella Vaccine Live/PF | D | $554K | +9% | 2,659 | $208 | $173.88 |
| Priorix Measles,Mumps,Rubella Vacc/PF | D | $230K | +527% | 2,181 | $105 | $98.63 |
| Activella Estradiol/Norethindrone Acet | D | $113K | -9% | 57 | $1,991 | $9.60 |
| Magellan Insulin Safety Syrng Syringe,Needle,Insuln,Safe,1ml | D | $13K | -41% | 63 | $211 | $0.44 |
| Ocella Ethinyl Estradiol/Drospirenone | D | $13K | -55% | 97 | $130 | $0.64 |
| Proquad Measles,Mumps,Rub,Varicella/PF | D | $10K | +92% | 38 | $258 | $261.20 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.